Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.

abstract：:Asthma is one of the most common respiratory diseases, where inhalation and exhalation are obstructed due to narrowing of the airways by broncho-constriction or by inflammation. Among all the available anti-asthma therapies, beta2-agonists are the most effective bronchodilators available, and give rapid relief of asth...

journal_title：Pharmacogenomics

authors： Bhatnagar P,Guleria R,Kukreti R

更新日期：2006-09-01 00:00:00

abstract：:The second Annual Meeting of the UK Pharmacogenetics and Stratified Medicine Network was held on 28 September 2011 at The Wellcome Trust Conference Centre on the Wellcome Trust Genome Campus at Hinxton, Cambridge, UK. The meeting preceded the annual Pharmacogenomics and Personalized Medicine conference, which was held...

journal_title：Pharmacogenomics

authors： Hall I

更新日期：2012-01-01 00:00:00

abstract：:Large interindividual variation in efficacy and adverse effects of anti-epileptic therapy presents opportunities and challenges in pharmacogenomics. Although the first true association of genetic polymorphism in drug-metabolizing enzymes with anti-epileptic drug dose was reported 10 years ago, most of the findings hav...

journal_title：Pharmacogenomics

authors： Kasperaviciūte D,Sisodiya SM

更新日期：2009-05-01 00:00:00

abstract：:Comprehensive, systematic and integrated data-centric statistical approaches to disease modeling can provide powerful frameworks for understanding disease etiology. Here, one such computational framework based on redescription mining in both its incarnations, static and dynamic, is discussed. The static framework prov...

journal_title：Pharmacogenomics

authors： Waltman P,Pearlman A,Mishra B

更新日期：2006-04-01 00:00:00

abstract：:The potential for personalized sequencing to individually optimize medical treatment in diseases such as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of sequencing healthy individuals for managing health is also being explored. The data produced requires additional advan...

journal_title：Pharmacogenomics

authors： Esplin ED,Oei L,Snyder MP

更新日期：2014-11-01 00:00:00

abstract：:This review deals with the pharmacological properties of an alkylated monosaccharide mimetic, N-butyldeoxynojirimycin (NB-DNJ). This compound is of pharmacogenetic interest because one of its biological effects in mice - impairment of spermatogenesis, leading to male infertility - depends greatly on the genetic backgr...

journal_title：Pharmacogenomics

authors： van der Spoel AC,Mott R,Platt FM

更新日期：2008-06-01 00:00:00

abstract：AIMS:The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. MATERIALS & METHODS:Towards this end, ABCG2 polymorphisms and expression were assessed in DNA an...

journal_title：Pharmacogenomics

authors： Lemos C,Giovannetti E,Zucali PA,Assaraf YG,Scheffer GL,van der Straaten T,D'Incecco A,Falcone A,Guchelaar HJ,Danesi R,Santoro A,Giaccone G,Tibaldi C,Peters GJ

更新日期：2011-02-01 00:00:00

abstract：INTRODUCTION:Warfarin is a widely prescribed, efficacious oral anticoagulant. S-warfarin, the more active form, is metabolized by the cytochrome P450 (CYP)2C9 enzyme. The aim was to evaluate the influence of two CYP2C9 functional polymorphisms (*2 and *3) on warfarin dose in African-Americans, an unstudied population a...

journal_title：Pharmacogenomics

authors： Kealey C,Chen Z,Christie J,Thorn CF,Whitehead AS,Price M,Samaha FF,Kimmel SE

更新日期：2007-03-01 00:00:00

abstract：:Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease susceptibility and 46 with impact in the clinical outcome of patients (p < 5.00 × 10-...

journal_title：Pharmacogenomics

authors： Pinto R,Assis J,Nogueira A,Pereira C,Pereira D,Medeiros R

更新日期：2017-11-01 00:00:00

abstract：:Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a ma...

journal_title：Pharmacogenomics

authors： Zuiverloon TC,Theodorescu D

更新日期：2017-08-01 00:00:00

abstract：UNLABELLED:Aim & patients & methods: This study investigated 24-h pharmacokinetic and CYP3A5 pharmacogenetic differences between once-daily tacrolimus (Tac-q.d.) versus twice-daily tacrolimus (Tac-b.i.d.) pretransplantation and at 1 month and 1 year post-transplantaion. RESULTS:The dose-adjusted trough level (Cmin) an...

journal_title：Pharmacogenomics

authors： Satoh S,Niioka T,Kagaya H,Numakura K,Inoue T,Saito M,Komine N,Narita S,Tsuchiya N,Habuchi T,Miura M

更新日期：2014-08-01 00:00:00

abstract：:Psoriasis vulgaris is one of the most prevalent T cell-mediated inflammatory diseases in humans. It is multifactorial in origin and shows polygenic inheritance. Systemic immunosuppressive therapies play an important role in management of severe disease cases but are associated with variable response and toxicity. With...

journal_title：Pharmacogenomics

authors： Ameen M

更新日期：2003-05-01 00:00:00

abstract：:The recent introduction of new microarray expression technologies and the further development of established platforms ensure that the researcher is presented with a range of options for performing an experiment. Whilst this has opened up the possibilities for future applications, such as exon-specific arrays, increas...

journal_title：Pharmacogenomics

authors： Elvidge G

更新日期：2006-01-01 00:00:00

abstract：:Cancer patients frequently suffer from disease- and treatment-related pain, nausea and depression, which severely reduces patients' quality of life. It is critical that clinicians are aware of drug-gene interactions and recognize the utility of applying pharmacogenetic information to personalize and improve supportive...

journal_title：Pharmacogenomics

authors： Andersen RL,Johnson DJ,Patel JN

更新日期：2016-03-01 00:00:00

abstract：:In the growing field of genomics, the utility of returning certain research results to participants has become a highly debated issue. Existing guidelines are not explicit as to the kind of genomic information that should be returned to research participants. Moreover, very few current recommendations and articles in ...

journal_title：Pharmacogenomics

authors： Korol S,Hurlimann T,Godard B,de Denus S

更新日期：2013-04-01 00:00:00

abstract：:A letter in response to: Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics 13(7), 757-762 (2012). ...

journal_title：Pharmacogenomics

authors： Botton MR,Hutz MH,Suarez-Kurtz G

更新日期：2012-11-01 00:00:00

abstract：OBJECTIVES:The aim of this study was to investigate whether the polymorphisms in the NR1I2 and ABCB1 genes were associated with epilepsy treatment responses. METHODS & RESULTS:NR1I2and ABCB1 polymorphisms were genotyped in 114 drug-resistant epileptic patients, 213 seizure-free patients and 287 normal controls. Highly...

journal_title：Pharmacogenomics

authors： Hung CC,Jen Tai J,Kao PJ,Lin MS,Liou HH

更新日期：2007-09-01 00:00:00

abstract：:The aim of this work was to determine the VKORC1 haplotype profile in healthy Hungarian and Roma population samples, and to compare our data with other selected populations. Using haplotype tagging SNPs (G-1639A, G9041A and C6009T), we characterized Hungarian (n = 510) and Roma (n = 451) population samples with regard...

journal_title：Pharmacogenomics

authors： Sipeky C,Csongei V,Jaromi L,Safrany E,Polgar N,Lakner L,Szabo M,Takacs I,Melegh B

更新日期：2009-06-01 00:00:00

abstract：:In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic...

journal_title：Pharmacogenomics

authors： Awada Z,Zgheib NK

更新日期：2014-04-01 00:00:00

abstract：AIM:Hemoglobinopathies exhibit a remarkable phenotypic diversity that restricts any safe association between molecular pathology and clinical outcomes. PATIENTS & METHODS:Herein, we explored the role of genes involved in the nitric oxide biosynthesis and signaling pathway, implicated in the increase of fetal hemoglobi...

journal_title：Pharmacogenomics

authors： Chalikiopoulou C,Tavianatou AG,Sgourou A,Kourakli A,Kelepouri D,Chrysanthakopoulou M,Kanelaki VK,Mourdoukoutas E,Siamoglou S,John A,Symeonidis A,Ali BR,Katsila T,Papachatzopoulou A,Patrinos GP

更新日期：2016-03-01 00:00:00

abstract：AIM:This study aimed to explore the role of miRNAs in rifampin-mediated induction of CYP3A4 in HepaRG cells. MATERIALS & METHODS:Microarray was performed to determine the expression of miRNAs in rifampin-treated HepaRG cells, followed by bioinformatics and luciferase reporter gene assay to analyze miRNAs that directly...

journal_title：Pharmacogenomics

authors： Yan L,Liu J,Zhao Y,Nie Y,Ma X,Kan Q,Zhang L

更新日期：2017-01-01 00:00:00

abstract：:The ultrarapid CYP2D6 metabolizer (UM) phenotype is caused by CYP2D6 gene duplications in some, but not all, UM individuals. CYP2D6 and the adjacent pseudogene CYP2D7 are highly homologous; however, CYP2D7 harbors a premature stop codon, which is absent in carriers of the rare CYP2D7 variant rs530303678. We addressed ...

journal_title：Pharmacogenomics

authors： Jukic MM,Lauschke VM,Saito T,Hiratsuka M,Ingelman-Sundberg M

更新日期：2018-08-01 00:00:00

abstract：:Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitu...

journal_title：Pharmacogenomics

authors： Klen J,Goričar K,Horvat S,Stojan J,Dolžan V

更新日期：2019-08-01 00:00:00

abstract：AIMS:To develop a novel warfarin-dosing algorithm based on a previous population pharmacokinetic/pharmacodynamic (PK/PD) model with Bayesian forecasting to facilitate warfarin therapy. MATERIALS & METHODS:Using information on CYP2C9 and VKORC1 genotypes, S-warfarin level, dose and international normalized ratio (INR) ...

journal_title：Pharmacogenomics

authors： Sasaki T,Tabuchi H,Higuchi S,Ieiri I

更新日期：2009-08-01 00:00:00

abstract：:This review will summarize the role of pharmacogenetics in the natural history of hepatitis C, particularly in patients with HIV/HCV and will take the perspective of pharmacogenetics and its influence on the response to antiviral therapy and the susceptibility to develop adverse effects. This review will also devote a...

journal_title：Pharmacogenomics

authors： Frias M,Rivero-Juárez A,López-López P,Rivero A

更新日期：2018-08-01 00:00:00

abstract：:Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. Approximately 5% of patients treated with abacavir develop a hypersensitivity reaction that requires discontinuation of the drug. In an initial pharmacogenetic study conducted in a predominantly White male population, multiple markers in the h...

journal_title：Pharmacogenomics

authors： Hughes AR,Mosteller M,Bansal AT,Davies K,Haneline SA,Lai EH,Nangle K,Scott T,Spreen WR,Warren LL,Roses AD,CNA30027 Study Team.,CNA30032 Study Team.

更新日期：2004-03-01 00:00:00

abstract：:The investigational drug dichloroacetate (DCA) is a metabolic regulator that has been successfully used to treat acquired and congenital metabolic diseases and, recently, solid tumors. Its clinical use has revealed challenges in selecting appropriate doses. Chronic administration of DCA leads to inhibition of DCA meta...

journal_title：Pharmacogenomics

authors： James MO,Stacpoole PW

更新日期：2016-05-01 00:00:00

abstract：:Pharmacogenomic analyses will become crucial to predict patients' toxicity to treatment and will also help to predict the tumor response. Processes of drug metabolism, drug efflux, DNA-repair and characteristics of drug targets are critical checkpoints of drug efficacy. These crucial pathways for drug action have been...

journal_title：Pharmacogenomics

authors： Stoehlmacher J,Goekkurt E,Lenz HJ

更新日期：2003-11-01 00:00:00

abstract：:The advent of multiplexing technologies has raised the possibility that disease states can be defined using discrete genomic and proteomic patterns or signatures. However, this emerging area has been limited by the 'content problem', arising from the uncertainty of which molecules to focus on. The human cluster of dif...

journal_title：Pharmacogenomics

authors： Woolfson A,Ellmark P,Chrisp JS,A Scott M,Christopherson RI

更新日期：2006-07-01 00:00:00

abstract：OBJECTIVES:The objective of this study was to assess the utility of the gene expression profiling technique for the preclinical evaluation of drug efficacy and safety, taking a new therapeutic approach for Duchenne muscular dystrophy (DMD) as an example. METHODS:Muscles from dystrophin-deficient (mdx) mice, a well-cha...

journal_title：Pharmacogenomics

authors： 't Hoen PA,van der Wees CG,Aartsma-Rus A,Turk R,Goyenvalle A,Danos O,Garcia L,van Ommen GJ,den Dunnen JT,van Deutekom JC

更新日期：2006-04-01 00:00:00